Servier et Taiho Oncology présentent des données sur la survie globale de trifluridine/tipiracil (LONSURF®) en association avec le bevacizumab chez des patients atteints d'un cancer colorectal métastatique réfractaire... | Business Wire
Trifluridine/Tipiracil Combination Misses Mark in Metastatic Colon Cancer | MedPage Today
Benefits & Risks of Treatment | Metastatic Colorectal Cancer (mCRC)| Avastin® (bevacizumab)
4. Cancer colorectal métastatique | SNFGE.org - Société savante médicale française d'hépato-gastroentérologie et d'oncologie digestive
NCCN® Guidelines for Metastatic Colon Cancer Treatment
Trifluridine/tipiracil: A practical guide to its use in the management of refractory metastatic colorectal cancer in Australia - Price - 2020 - Asia-Pacific Journal of Clinical Oncology - Wiley Online Library
Lonsurf® Treatment for Colorectal Cancer - CancerConnect
How does chemo fit into my treatment plan? - Colontown University
Trifluridine/tipiracil plus bevacizumab prolongs survival in refractory colorectal cancer
First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study | British Journal of Cancer
Third-Line Treatment for Metastatic Colorectal Cancer | LONSURF® (trifluridine and tipiracil) tablets
TAS-102 plus bevacizumab: a new standard for metastatic colorectal cancer? - The Lancet Oncology
First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study | British Journal of Cancer
NEJM on X: "This editorial describes the science behind a clinical trial performed by Prager and colleagues: a test of trifluridine–tipiracil and bevacizumab to treat patients with refractory metastatic colorectal cancer. https://t.co/Y1QlV28qsr" /
Avastin and Lonsurf for Advanced Colorectal Cancer - NCI
How to Take LONSURF® (trifluridine and tipiracil) tablets | Helpful Dosage Reminders
Servier et Taiho Oncology présentent des données sur la survie globale de trifluridine/tipiracil (LONSURF®) en association avec le bevacizumab chez des patients atteints d'un cancer colorectal métastatique réfractaire... | Business Wire
First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study | British Journal of Cancer
Lonsurf (Trifluridine plus Tipiracil): A New Oral Treatment Approved for Patients with Metastatic Colorectal Cancer
La trifluridine plus le tipiracil et le bévacizumab est une nouvelle norme de soins pour le cancer colorectal métastatique réfractaire
These highlights do not include all the information needed to use LONSURF safely and effectively. See full prescribing information for LONSURF. LONSURF (trifluridine and tipiracil) tablets, for oral use Initial U.S. Approval:
Current Oncology | Free Full-Text | A Systematic Review and Meta-Analysis of Trifluridine/Tipiracil plus Bevacizumab for the Treatment of Metastatic Colorectal Cancer: Evidence from Real-World Series
LONSURF® (trifluridine and tipiracil) tablets | Previously Treated mCRC Treatment | TAS-102 Efficacy
